Skip to main content

Advertisement

Table 1 Patient baseline characteristics (n = 36)

From: Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Variable Overall
Age 52 (12)
Sex
 Male 12 (33 %)
 Female 24 (67 %)
Stage
 IVa 4 (11 %)
 IVb 2 (6 %)
 IVc 30 (83 %)
Primary site
 Cutaneous 28 (78 %)
 Acral 4 (11 %)
 Mucosal 0 (0 %)
 Unknown 4 (11 %)
Treatment
 Dabrafenib + trametinib 34 (94 %)
 Dabrafenib 2 (6 %)
 Vemurafenib 0 (0 %)
 Re-challenge dabrafenib + trametiniba 8 (22 %)
First plasma sample
 Before initiation of targeted therapy 16 (44 %)
 After initiation of targeted therapy 20 (56 %)
  1. Data are mean (SD) or n (%).
  2. Baseline characteristics at the moment of collection of the first plasma sample
  3. aEight patients were treated with dabrafenib and trametinib after documentation of disease progression at least 12 weeks following the last day of dosing of a BRAF-inhibitor containing treatment regimen (ClinicalTrials.gov Identifier:NCT02296996)